Iron sucrose: The oldest iron therapy becomes new

American Journal of Kidney Diseases

Volumn 40, Issue 6, 2002, Pages 1111-1121

  Yee, Jerry ^a   Besarab, Anatole ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anaphylactoid reaction; Chronic kidney disease (CKD); End stage renal disease (ESRD); Hemodialysis (HD); Iron dextran; Iron gluconate; Iron sucrose

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERRUM VITIS; IRON DEXTRAN; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; CHILL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; HEMODIALYSIS; HUMAN; HYPOTENSION; IRON THERAPY; MOLECULAR WEIGHT; NAUSEA; PARESTHESIA; PRURITUS; RASH; REVIEW; STRIDOR; SYNCOPE; TASTE DISORDER; THORAX PAIN; URTICARIA; WHEEZING;

EID: 0036896348     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.36853     Document Type: Article

References (71)

1. Ebert BL, Bunn HF: Regulation of the erythropoietin gene. Blood 94:1864-1877, 1999
2. Shiose A, Kuroda J, Tsuruya K, et al: A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276:1417-1423, 2001
3. Geiszt M, Kopp JB, Várnai P, Leto T: Identification of Renox, an NADPH oxidase in kidney. Proc Natl Acad Sci U S A 97:8010-8014, 2000
4. Van Wyck DB: Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 14:9-13, 1989
5. Tarng DC, Chen TW, Huang TP: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
6. Kleiner MJ, Van Wyck DB, Kaupke CJ, Kirlin LF: The role of iron and other factors in patients unresponsive to erythropoietin therapy. Semin Dial 8:29-34, 1995
7. Macdougall IC: Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 10:607-614, 1995
8. Besarab A, Frinak SJ, Yee J: An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10:2029-2043, 1999
9. Fishbane S, Wagner J: Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 37:879-883, 2001
10. Danielson BG, Geisser P, Schneider W: Iron Therapy. St Gallen, Switzerland, Vifor, 1996, pp 55-62
11. Van Wyck DB, Anderson J, Johnson K: IV iron agents donate iron to transferring in vitro. J Am Soc Nephrol 417A-418A, 2001 (abstr)
12. Danielson BG, Salmonson T, Derendorf H, Geisser P: Pharmacokinetics of iron (III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46:615-621, 1996
13. Sunder-Plassman G, Hörl WH: Comparative look at intravenous iron agents: Pharmacology, efficacy, and safety of iron dextran, iron saccharate, and ferric gluconate. Semin Dial 12:243-248, 1999
14. Campbell BC, Lawrence JR, Sumner DJ, et al: A pharmocokinetic and clinical evaluation of iron poly (sorbitolgluconic acid) complex. Pharmatherapeutica 2:475-480, 1980
15. Kanakakorn K, Cavill I, Jacobs A: The metabolism of intravenously administered iron-dextran. J Haematol 25:637-643, 1973
16. 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography. Br J Haematol 104:288-295, 1999
17. Geisser P, Baer M, Schaub E: Structure histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 42:1439-1452, 1992
18. Charytan C, Levin N, Al-Saloum M, et al: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 37:300-307, 2001
19. Seligman PA, Schleicher RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 45:898-901, 1999
20. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34:21-28, 1999
21. Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 35:1-12, 2000
22. Chandler G, Orlaith E, Davis CM, Williams K, Macdougall IC: Can higher doses of IV iron be given as a bolus injection. J Am Soc Nephrol 12:260A, 2001 (abstr)
23. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 33:471-482, 1999
24. Iron Hydroxide Sucrose Complex in Water (Venofer®) [package insert]. Shirley, NY, American Regent Laboratories, 2001
25. Sodium ferric gluconate complex in sucrose injection (Ferrlecit) [package insert]. Corona, CA, Watson Pharmaceuticals Inc. and Marina Del Ray, CA, R & D Laboratories Inc, 2001
26. St Peter WL, Lambrecht LJ, Macres M: Randomized crossover study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28:523-528, 1996
27. Paschen HW: Efficient anemia treatment with large intravenous iron doses. Geburtshilse Frauenheilkunde 9:604-616, 1999
28. Weisbach V, Skoda P, Rippel R, et al: Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: A randomized, controlled study. Transfusion 39:465-472, 1999
29. Silverberg DS, Iaina A, Peer G, Kaplan E: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
30. Van Wyck DB, Stivelman JC, Ruiz J, Kurlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis associated anemia. Kidney Int 35:712-716, 1989
31. Pascual J, Teruel JL, Liano F, Sureda A, Ortuno J: Intravenous Fe gluconate-Na for iron deficient patients on hemodialysis. Nephron 60:121, 1992 (letter)
32. Magana L, Dhar SK, Smith EC, Martinez C: Iron absorption and utilization in maintenance hemodialysis patients: Oral and intravenous routes. Mt Sinai J Med 51:180-183, 1984
33. Stoves J, Inglis H, Newstead CG: A randomized study of oral vs intravenous supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16:967-974, 2001
34. Silverberg DS, Blum M, Peer G, Kaplan E, Aiana A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996
35. Besarab A, Amin N, Ahsan M, et al: Optimization of epoetin therapy with intravenous iron in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
36. Fishbane S, Ungureanu V, Maesaka J, Kaupke CJ, Lim V, Wish J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996
37. Van Wyck DB: Lessons from NKF-DOQI: Iron management. Semin Nephrol 20:330-334, 2000
38. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM: A randomized controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16:1239-1244, 2001
39. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:24122414, 2001
40. Hasselwander O, Young IS: Oxidative stress in chronic renal failure. Free Radic Res 29:1-11, 1997
41. Roselaar SE, Nazhat NG, Winyard PG, Jones P, Cunningham J, Blake DR: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
42. Van Wyck DB, Cavallo G, Spinowitz BS, et al: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36:88-97, 2000
43. Fleming LW, Stewart WK, Parratt D: Dextran antibodies, complement conversion, and circulating immune complexes after intravenous iron dextran therapy in dialyzed patients. Nephrol Dial Transplant 7:35-39, 1992
44. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464-470, 1999
45. Food and Drug Administration: Adverse Event Reporting System (AERS); Freedom of Information (FOI) Report. Rockville, MD, Food and Drug Administration, July 9, 2001
46. Macdougall I, Bailie G, Richardson D, Tanner J, Gagnon SP: Worldwide safety profile of iron sucrose injection (Venofer®): Analysis of 1,004,477 patients from 1992 to 2001. J Am Soc Nephrol 12:333A, 2001 (abstr)
47. Lunde N, Pennell P, Charytan C, Hood S, Yee J: Safety of iron sucrose in the general hemodialysis population. J Am Soc Nephrol 12:359A-360A, 2001 (abstr)
48. Warnock DG, Coyne DW, Michael B, Strobos JT: Administration of sodium ferric gluconate complex to irondextran-sensitive hemodialysis patients. J Am Soc Nephrol 12:365A, 2001 (abstr)
49. Charytan C, Spinowitz BS, Al-Saloum M, BheemReddy S, Murugan T: Iron sucrose may be safely administered to dialysis patients intolerant to other parenteral iron products. J Am Soc Nephrol 12:353A, 2001 (abstr)
50. McCord JM: Superoxide production and human disease, in Jesaitis A, Dratz E (eds): Molecular Basis of Oxidative Damage by Leukocytes. Boca Raton, FL, CRC, 1992, pp 225-239
51. Thomas CE, Morehouse LA, Aust SD: Ferritin and superoxide-dependent lipid peroxidation. J Biol Chem 260: 3275-3280, 1985
52. Biemond P, van Eijk HG, Swaak AG, et al: Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. J Clin Invest 73:1576-1579, 1984
53. Cord JM: Free radicals and inflammation: Protection of synovial fluid by superoxide dysmutase. Science 185:529531, 1974
54. Cristol JP, Bosc JY, Badiou S, et al: Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12:2312-2317, 1997
55. Peuchant E, Carbonneau MA, Dubourg L, et al: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: Vitamins A, E, and iron status. Free Radic Biol Med 16:339-346, 1994
56. Corti M-C, Gaziano M, Henekens CH: Iron status and the risk of cardiovascular disease. Ann Epidemiol 7:62-68, 1997
57. Collins A, Ebben J, Ma J: Frequent IV iron dosing is associated with higher infectious deaths. J Am Soc Nephrol 8:190A, 1997 (abstr)
58. Becker RN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other nontraditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
59. Boelaert JR, Daneels RF, Schurgers ML, et al: Iron overload in haemodialysis patients increases the risk for bacteremia: A prospective study. Nephrol Dial Transplant 5:130-134, 1990
60. Tielmans CL, Lenclud CM, Wens R, Collart FE, Dratwa M: Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4:883-887, 1989
61. Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem JL: Impairment of phagocytic oxidative metabolism in hemodialysis patients with iron overload. Clin Nephrol 25:227-230, 1986
62. Patruta SI, Edlinger R, Sunder-Plassman G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
63. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin: Results of a combined phase I and phase II clinical trial. N Engl J Med 316:73-78, 1987
64. Parkkinen J, von Bonsdorff L, Peltonen S, GrönhagenRisk C, Rosenlöf K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after IV ironsaccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000
65. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D: The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol 21:617-622, 1971
66. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Soc Nephrol 38:988-991, 2001
67. Folkert FW, Michael B: Safety of sodium ferric gluconate complex in higher individual doses. J Am Soc Nephrol 12:379A, 2001 (abstr)
68. Bastani B, Jain A, Pandurangan G: The incidence of side effects associated with high-dose ferric gluconate (Ferrlecit) in patients with severe chronic renal failure (CRF). Am J Kidney Dis 37:12A, 2001 (abstr)
69. Nyvad O, Danielsen H, Madsen S: Intravenous ironsucrose complex to reduce epoetin demand in dialysis patients. Lancet 344:1305-1306, 1994
70. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, Ungkanont A, Bunyaratvej A: Indices of iron status in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 34:39-35, 1999
71. Asuncion MJ, Arruda JAL, Lash JP: "High dose" sodium ferric gluconate (Ferrlecit®) is safe and effective in peritoneal dialysis patients. J Am Soc Nephrol 12:357A, 2001 (abstr)